Imagion Biosystems Limited IBXXF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -42.58% | -81.94% | -97.31% | -86.95% | -82.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.58% | -81.94% | -97.31% | -86.95% | -82.00% |
| Cost of Revenue | 383.73% | 397.75% | 416.77% | -27.21% | -80.39% |
| Gross Profit | -740.76% | -270.60% | -188.25% | -133.50% | -84.15% |
| SG&A Expenses | 23.26% | -21.95% | -44.76% | -71.21% | -81.00% |
| Depreciation & Amortization | -46.84% | -96.32% | -97.83% | -98.51% | -98.77% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 141.75% | 54.31% | 3.35% | -62.53% | -82.36% |
| Operating Income | -350.82% | -358.61% | -362.95% | 28.52% | 82.74% |
| Income Before Tax | -121.66% | -113.94% | -104.72% | 23.72% | 65.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -121.66% | -113.94% | -104.72% | 23.72% | 65.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.66% | -113.94% | -104.72% | 23.72% | 65.89% |
| EBIT | -350.82% | -358.61% | -362.95% | 28.52% | 82.74% |
| EBITDA | -397.93% | -588.21% | -1,143.02% | 6.05% | 80.95% |
| EPS Basic | 32.17% | 62.96% | 72.51% | 86.78% | 90.90% |
| Normalized Basic EPS | 33.33% | 62.91% | 72.73% | 86.86% | 90.89% |
| EPS Diluted | 32.76% | 62.55% | 72.24% | 86.66% | 90.82% |
| Normalized Diluted EPS | 33.33% | 62.91% | 72.73% | 86.86% | 90.89% |
| Average Basic Shares Outstanding | 226.41% | 301.45% | 517.31% | 423.97% | 295.60% |
| Average Diluted Shares Outstanding | 226.41% | 301.45% | 517.31% | 423.97% | 295.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |